EML5

Across TCGA pan-cancer cohorts, EML5 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EML5 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher EML5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EML5 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

MESO, HNSC, and UCEC are the cancer types where EML5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.098	0.579	.001	30	view →
HNSC	DFS	Median	IV	0.078	0.670	<.001	6	view →
UCEC	DFS	Median	All	0.904	0.607	.019	6	view →
BRCA	OS	Median	III,IV	0.644	0.907	.025	3	view →
SKCM	OS	Median	All	0.950	0.866	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EML5–MESO (OS)

Open the MESO breakdown →